Literature DB >> 2984241

Comparison of a latex agglutination test with five other methods for determining the presence of antibody against cytomegalovirus.

D G Beckwith, D C Halstead, K Alpaugh, A Schweder, D A Blount-Fronefield, K Toth.   

Abstract

A latex agglutination test for determination of antibody against cytomegalovirus was compared with five other methods: a solid-phase fluorescent immunoassay, an indirect hemagglutination test, two solid-phase enzyme immunoassays, and an indirect fluorescent-antibody method, with sera collected from 210 random blood donors. Of the sera tested, 28% were positive for anti-cytomegalovirus by concordance of four or more methods. The latex agglutination test performed well, with a sensitivity of 100%, a specificity of 99%, and positive and negative predictive values of 97 and 100%, respectively. The methods were also evaluated for the number of sera requiring repeat testing, equivocal results after retesting, ease of performance, turnaround time, and technical demands. The tests which best met the requirements for a screening test were the solid-phase fluorescent immunoassay, the indirect hemagglutination test, and the latex agglutination test. The latex agglutination test is a valuable screening tool for detecting total anti-cytomegalovirus which has high sensitivity, high negative predictive value, and rare equivocal results and also has the added advantages of ease of performance and rapid turnaround time.

Mesh:

Substances:

Year:  1985        PMID: 2984241      PMCID: PMC271657          DOI: 10.1128/jcm.21.3.328-331.1985

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Cytomegalovirus and blood transfusion in neonates.

Authors:  J W Benson; S J Bodden; J O Tobin
Journal:  Arch Dis Child       Date:  1979-07       Impact factor: 3.791

2.  Disease due to cytomegalovirus and its long-term consequences in renal transplant recipients. Correlation of allograft survival with disease due to cytomegalovirus and rubella antibody level.

Authors:  J P Luby; A J Ware; A R Hull; J H Helderman; P Gailiunas; S Butler; C Atkins
Journal:  Arch Intern Med       Date:  1983-06

Review 3.  Assessment of human cytomegalovirus antibody detection techniques.

Authors:  F Horodniceanu; S Michelson
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

4.  Prevention of transfusion-associated cytomegalovirus infection in very low-birthweight infants using frozen blood and donors seronegative for cytomegalovirus.

Authors:  S P Adler; L T Lawrence; J Baggett; V Biro; D E Sharp
Journal:  Transfusion       Date:  1984 Jul-Aug       Impact factor: 3.157

5.  Prevention of transfusion-acquired cytomegalovirus infections in newborn infants.

Authors:  A S Yeager; F C Grumet; E B Hafleigh; A M Arvin; J S Bradley; C G Prober
Journal:  J Pediatr       Date:  1981-02       Impact factor: 4.406

6.  Cytomegalovirus infections associated with leukocyte transfusions.

Authors:  D J Winston; W G Ho; C L Howell; M J Miller; R Mickey; W J Martin; C H Lin; R P Gale
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

7.  Use of enzyme immunoassays and the latex agglutination test to measure the temporal appearance of immunoglobulin G and M antibodies after natural infection or immunization with rubella virus.

Authors:  J M Meegan; B K Evans; D M Horstmann
Journal:  J Clin Microbiol       Date:  1983-09       Impact factor: 5.948

8.  Latex agglutination test for measurement of antibodies to meningococcal polysaccharides.

Authors:  E C Tramont; M S Artenstein
Journal:  Infect Immun       Date:  1972-03       Impact factor: 3.441

9.  Acquisition of cytomegalovirus infection in infants following exchange transfusion: a prospective study.

Authors:  A Kumar; G A Nankervis; A R Cooper; E Gold; M L Kumar
Journal:  Transfusion       Date:  1980 May-Jun       Impact factor: 3.157

10.  Latex-Rickettsia rickettsii test reactivity in seropositive patients.

Authors:  K E Hechemy; B B Rubin
Journal:  J Clin Microbiol       Date:  1983-03       Impact factor: 5.948

View more
  8 in total

1.  Evaluation of four methods for cytomegalovirus antibody detection for use by a bone marrow transplantation service.

Authors:  D S Leland; K A Barth; E B Cunningham; J Jansen; G J Tricot; M L French
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

2.  Microparticle enzyme immunoassay for determination of immunoglobulin G antibodies to human cytomegalovirus.

Authors:  G Duverlie; C Roussel; M Driencourt; J Orfila
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

3.  Latex agglutination and enzyme-linked immunosorbent assays for cytomegalovirus serologic screening of transplant donors and recipients.

Authors:  S W Chou; K M Scott
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

4.  Comparison of four methods for screening of cytomegalovirus antibodies in normal donors and immunocompromised patients.

Authors:  F de Ory; P León; C Domingo; A Garcia-Sáiz; L Pérez; J M Echevarría
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

5.  Comparison of six methods for the detection of antibody to cytomegalovirus.

Authors:  T M McHugh; C H Casavant; J C Wilber; D P Stites
Journal:  J Clin Microbiol       Date:  1985-12       Impact factor: 5.948

6.  Rapid dot enzyme immunoassay for the detection of antibodies to cytomegalovirus.

Authors:  T M Lin; S P Halbert
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

7.  Evaluation of the CMV-CUBE assay for detection of cytomegalovirus serologic status in marrow transplant patients and marrow donors.

Authors:  C A Gleaves; S F Wendt; D R Dobbs; J D Meyers
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

8.  Evaluation of a latex particle agglutination assay for the detection of cytomegalovirus antibody in patient serum.

Authors:  D A Hursh; A D Abbot; R Sun; J P Iltis; D H Rice; C A Gleaves
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.